Miura N, Nakata N, Tanaka Y, Hiraga Y, Ikeda Y, Ohata H, Iwasaki T
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., Saitama, Japan.
Jpn J Pharmacol. 1993 Jun;62(2):203-6. doi: 10.1254/jjp.62.203.
A novel serotonin reuptake inhibitor, (-)trans 4-(4-fluorophenyl)-3-(4-methoxyphenoxy-methyl)piperidine hydrochloride (FG-7080), was investigated for its effects on scopolamine-induced impairments in memory tasks of rats. In the radial-arm maze task, FG-7080 (3 mg/kg, p.o.) improved the impaired performance. FG-7080 (1 mg/kg, p.o.) administered before the acquisition trial reduced the acquisition deficits in the passive avoidance task. Thus, the compound showed improving effects in the appetitive and aversive memory tasks. These findings suggest that FG-7080 may ameliorate the cognitive impairments caused by the cholinergic dysfunction.
一种新型血清素再摄取抑制剂，（-）反式4-（4-氟苯基）-3-（4-甲氧基苯氧基甲基）哌啶盐酸盐（FG-7080），被研究了其对东莨菪碱诱导的大鼠记忆任务损伤的影响。在放射状臂迷宫任务中，FG-7080（3毫克/千克，口服）改善了受损的表现。在获得性试验前给予FG-7080（1毫克/千克，口服）减少了被动回避任务中的获得性缺陷。因此，该化合物在食欲性和厌恶性记忆任务中显示出改善作用。这些发现表明FG-7080可能改善由胆碱能功能障碍引起的认知损伤。
